Institute for State Control of Veterinary Biologicals and Medicines
Hudcova 56a, 621 00 Brno, Czech Republic

(Reference Member State – CZ)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Ralcam 100 mg/ml + 0.05 mg/ml solution for injection for cattle (CZ)
Catobevit 100 mg/ml + 0.05 mg/ml solution for injection for cattle (DE)

MODULE 1

PRODUCT SUMMARY

EU Procedure number	CZ/V/0160/001/DC
Name, strength and pharmaceutical form	Catobevit 100 mg/ml + 0.05 mg/ml solution for injection for cattle (DE) Ralcam 100 mg/ml + 0.05 mg/ml solution for injection for cattle (CZ)
Applicant	KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Active substance(s)	Butafosfan, Cyanocobalamin (vitamin B12)
ATC vet code	QA12CX99
Target species	Cattle
Indication for use	For the supportive treatment of secondary ketosis (e. g. in abomasal displacement).

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13.1. of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	03/06/2019
Date product first authorised in the Reference Member State (MRP only)	NA
Concerned Member States for original procedure	DE

I. SCIENTIFIC OVERVIEW

***For public assessment reports for the first authorisation in a range**:*

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains Butafosfan 100 mg/mL and Cyanocobalamin 0.05 mg/mL and the excipients Phenol, Sodium hydroxide and Water for injections.

The container-closure system is 100mL amber type II glass bottles and 250mL amber type I glass bottles closed with bromobutyl rubber stoppers and flip-off seals.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site. The manufacturing process is adequately described including quantities of materials, process conditions and in-process controls.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substances are Butafosfan and Cyanocabalemin, which are both established active substances. Butafosfan is not described in Ph. Eur. neither in pharmacopoeia of any EU member state and it is thus controlled as per justified in-house specification. Cyanocobalamin is described in the Ph. Eur. and it is controlled accordingly.

The active substances are manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Scientific data are provided for Butaphosphan using ASMF procedure. Certificate of suitability issued by the EDQM have been provided for Cyanocobalamin. There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate products

Not applicable

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

The control methods are adequately described. Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substances have been provided in accordance with applicable European guidelines. The stability data support the claimed retest periods for the active substances.

Stability data on the finished product have been provided in accordance with applicable European guidelines. The stability data support the claimed shelf-life and storage conditions.

In-use shelf-life after first opening the vial is supported by adequate in-use stability study.

G. Other Information

Additional summary information is given on potential presence of residual solvents considering each component of the product formulation. Compliance with the Ph. Eur. is demonstrated.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to 13(1) of Directive 2001/82/EC as amended results of safety tests are not required.

III.A Safety Testing

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

Phase I

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines. The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the active substances are natural substances, the use of which will not alter the concentration or distribution of the substance in the environment. Warnings and precautions as listed on the product literature are adequate to ensure safety to environment of the product.

III.B Residues documentation

Residue Studies

The applicant has submitted the generic application in accordance with Article 13(1) of Directive 2001/82/EC, as amended. No residue depletion studies were required at this case. The product is intended for cattle.

MRLs

According to the Annex I of Commission Regulation (EU) No. 37/2010 – following MRLs have been established for the active substance:

Pharmacologically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions
Butafosfan	Not applicable	All mammalian food producing species	No MRL required	Not applicable	No entry
Vitamin B12	Not applicable	All food producing species	No MRL required	Not applicable	No entry

Withdrawal Periods

Based on information above, the following withdrawal periods were approved for cattle:

Withdrawal period(s):

Meat and offal: zero days
Milk: zero hours

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

None